Here is the latest issue of Prostate Cancer Communication. It is a publication from PAACT (Patient Advocates for Advanced Cancer Treatments). There are some good articles that may be of interest to you.
From PBS interview with Dr .Elisabeth Rosenthal. 6 Questions to ask your doctor.
A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy.
- PSA density was a much more accurate predictor of risk than PSA alone for all men with a PSA level of 4 ng/ml or higher.
- Among men with a PSA level of < 4 ng/ml, PSA density was no better than PSA at predicting actual prostate cancer (of any type or of clinical significance).
The minimally invasive treatment uses steam to kill cells and shrink the prostate and can be used on a wider range of anatomies.
Early results in clinical practice on large prostates appear “promising” and a study on prostates up to 150 grams is expected to begin later this year.
Genomic testing is done on cancerous tissue taken from the prostate in order to provide information about how your prostate cancer might behave. By looking at the genetic makeup of the cancer, these tests may help predict whether your prostate cancer grows slowly or aggressively.
Genomic testing can be performed on both biopsy tissue and on tissue from an entire prostate following a prostatectomy.